Transplantation Direct June 2021 Issue

JUST RELEASED - TRANSPLANTATION DIRECT - JUNE ISSUE

The June issue of Transplantation Direct is available online. The issue starts out with a review on the impact frailty is currently having on outcomes in kidney transplantation. Also in kidney transplantation, studies examine the potential effects steroid withdrawal has on therapeutic tacrolimus levels, and look at the effects transplant biopsy itself has on donor-derived cell-free DNA measurements. In liver transplantation, a case is presented which alerts transplant clinicians about potential organ perfusion anaphylaxis caused by machine perfusion with epoprostenol, and in experimental lung transplantation (cynomolgus macaques), there is an interesting report on lack of immunological tolerance using a modern mixed-chimerism protocol that was reportedly effective for kidney transplants. Another investigation looks at whether IVIG treatment can affect screening for donor-specific antibodies in patients. On the topic of organ donation, the experimental effects of donor age (in rats) in the DCD setting on ischemic heart damage are tested; there are also reports on a case of multi-organ donation after liquid nicotine intoxication, and on a pilot program aimed to optimize overweight/steatotic donors for living liver donation. Related to infectious diseases impacting transplantation, an evaluation of SRTR data in the U.S. provides interesting data on the geographic distribution of CMV risk. For complete details on these articles, and more, please visit our open access Transplantation Direct website.

CLICK HERE TO ACCESS THIS ISSUE


Starting June 14, Join us for the TTS Masterclass Series

Delivered by the world’s best known and regional experts, each Masterclass includes presentations by an international and a regional expert to bring perspective to the topic, highlight differences and opportunities, and bolster active discussions.

IPITA 2021 Virtual Congress - Abstract Deadline

We invite you to submit your abstract to the IPITA 2021 and be part of an engaging scientific program presenting cutting-edge clinical data and updates on state-of-the-art research.

Key facts you should know:

  • Abstracts will be accepted as either an oral or an e-poster presentation.
  • E-posters will include a 1-minute pitch video showcased in the virtual e-poster lounge.
  • By submitting an abstract, you will have the opportunity to win one of the IPITA 2021 Congress Awards!
  • We are planning a “Best Poster Showdown” session during which presenters of abstracts shortlisted for an award will have the opportunity to interact live with the audience and compete for the “Best Poster Abstract Award”. A total of three “Best Poster Abstract Awards” will be bestowed, one for each of the main congress themes (Pancreas Transplant; Islet Transplant; Stem Cell and Regenerative Medicine).
  • This year we also welcome abstracts under the topic of “COVID, Pancreas and Islet Transplantation and Diabetes”. Top-rated abstracts under this category will be presented during the pre-congress COVID-19 workshop.
  • Accepted abstracts will be published in an online supplement of the Transplantation Journal (subject to author approval).

Hot off the Press 

«HOT OFF THE PRESS» 
RECENT PUBLICATIONS IDENTIFIED
BY TTS EDUCATION COMMITTEE ON COVID-19

Selected Publications by TTS Education Committee. This week's selection made by Drs. Enver Akalin, Marlies Reinders and Millie Samaniego.

Seroconversion Rates Following Covid-19 Vaccination Amongst Patients with Cancer

Astha Thakkar et al.
Cancer Cel (2021) doi: https://doi.org/10.1016/j.ccell.2021.06.002.
This study reported a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. Comparing to solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematological malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post-vaccination. These results indicate a higher response rate to COVID-19 vaccines in patients with cancer compared to solid organ transplantation reported between 30-57%.

Cellular and Humoral Response after Mrna-1273 Sars-Cov-2 Vaccine in Kidney Transplant Recipients

David Cucchiari et al.
AmJT, 2021 May 26. doi: 10.1111/ajt.16701. Online ahead of print. PMID: 34036720
This study analyzed 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and two weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine. At baseline, 31 patients (20.9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-preimmunized, while 117 (79.1%) patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S-ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with anti-thymocytes globulins during the last year.

IN THE NEWS 


Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada